Genome & Co.

Genome & Co.

KKRX:314130
2,920.00
KRW
-45.00
(-1.52%)
-1,209.61EPS
138.70BMarket Cap

Total Valuation

KRW

As of June 30, 2026, Genome & Co. carries a market capitalization of 138.70B, placing it among publicly traded companies globally. Its enterprise value stands at 113.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap138.70B
Enterprise Value113.43B

Share Statistics

As of June 30, 2026, Genome & Co. has 35.93M shares outstanding.

Shares Outstanding35.93M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 5.63, and the price-to-book ratio stands at 2.07.

PS Ratio5.63
PB Ratio2.07
P/TBV Ratio2.69
P/FCF Ratio-7.55
P/OCF Ratio-7.85

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 4.64 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 113.43B versus a market cap of 138.70B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.64

Financial Position

As of June 30, 2026, Genome & Co. maintains a current ratio of 2.31, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 30.52, indicating elevated leverage, while an interest coverage ratio of -5.54 demonstrates limited ability to service its debt obligations.

Current Ratio2.31
Quick Ratio1.88
Debt / Equity30.52
Debt / EBITDA-1.07
Interest Coverage-5.54

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, Genome & Co. posted a negative return on equity (ROE) of -57.75, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.18, reflecting losses generated across the asset base. The company generates approximately 250.88M in revenue per employee across its workforce of 97.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.41 indicates how many times Genome & Co. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-57.75
Return on Assets (ROA)-31.18
Revenue Per Employee250.88M
Employee Count97.50
Inventory Turnover1.41

Taxes

KRW

Over the twelve months ended June 30, 2026, Genome & Co. recorded an income tax benefit of -1.40B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -44.58B and -41.36B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-1.40B

Stock Price Statistics

KRW

As of the close on November 17, 2026, Genome & Co.'s stock has declined approximately 2.18% over the past 52 weeks. The 50-day moving average sits at 3,951.50, while the 200-day moving average is 5,527.58.

52-Week Price Change-2.18%
50-Day Moving Average3,951.50
200-Day Moving Average5,527.58

Income Statement

KRW

Over the twelve months ended June 30, 2026, Genome & Co. generated 24.46B in revenue and converted that into -41.36B in net income, yielding earnings per share of -1,209.61. EBITDA reached -23.17B, while operating income came in at -29.19B.

Revenue24.46B
Gross Profit13.33B
Operating Income-29.19B
Pretax Income-44.58B
Net Income-41.36B
EBITDA-23.17B
EBIT-29.19B
Earnings Per Share (EPS)-1,209.61

Balance Sheet

KRW

As of June 30, 2026, Genome & Co. holds 64.30B in cash and equivalents against 24.81B in total debt, resulting in a net debt position of -28.49B. Total book value stands at 67.08B, with working capital of 44.90B providing operational flexibility.

Cash & Cash Equivalents64.30B
Total Debt24.81B
Net Debt-28.49B
Equity (Book Value)67.08B
Book Value Per Share1,866.85
Working Capital44.90B

Cash Flow

KRW

Genome & Co. produced -17.55B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -714.26M in capital expenditures, free cash flow totaled -18.26B - equivalent to -511.59 per share.

Operating Cash Flow-17.55B
Capital Expenditures-714.26M
Free Cash Flow-18.26B
FCF Per Share-511.59

Margins

Over the twelve months ended June 30, 2026, Genome & Co. posted a gross margin of 54.50, reflecting its pricing power and cost economics. The operating margin of -119.33 and net profit margin of -169.09 provide insight into operational efficiency.

Gross Margin54.50
Operating Margin-119.33
Pretax Margin-182.27
Profit Margin-169.09
EBITDA Margin-94.72

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -13.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -22.23, meaning Genome & Co. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-22.23
FCF Yield-13.25

Stock Splits

Genome & Co.'s most recent stock split took place on August 6, 2024 with a 1:2 split ratio.

Last Split Date8/6/2024
Split Ratio1:2

Scores

As of June 30, 2026, Genome & Co. has an Altman Z-Score of -2.86, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-2.86